A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.

Journal: Immunity

Published: 2020-07-30

DOI: 10.1016/j.immuni.2020.07.019

Affiliations: 14

Authors: 42

Go to article
Institutions Share
Bioqual, Inc., United States of America (USA) 0.17
Duke Human Vaccine Institute (DHVI), United States of America (USA) 0.15
Department of Microbiology, Penn, United States of America (USA) 0.14
Department of Medicine, Penn, United States of America (USA) 0.13
Department of Immunology and Microbiology, Scripps Research Florida, United States of America (USA) 0.10
Department of Microbiology, ISMMS, United States of America (USA) 0.08
Research Institute, CHOP, United States of America (USA) 0.06
Department of Pathology and Laboratory Medicine, Penn, United States of America (USA) 0.06
Acuitas Therapeutics, Canada 0.05
Facultad de Medicina, UdeA, Colombia 0.01
Graduate School of Biomedical Sciences, ISMMS, United States of America (USA) 0.01
BioNTech RNA Pharmaceuticals, Germany 0.01
Duke Department of Pathology, United States of America (USA) 0.01
School of Veterinary Medicine (Penn Vet), United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER